Details

Autor(en) / Beteiligte

• Ali, Salhah
• Al-Qattan, Yasmine
• Awny, Walaa
• Hamadah, Abdulaziz
• Pinto, Karen
• AlShemmari, Salem

Titel

FIP1L1-PDGFRA fusion gene in T-lymphoblastic lymphoma: A case report

Ist Teil von

• Cancer reports (Hoboken, N.J.), 2023, Vol.6 (1), p.e1769-e1769

Erscheinungsjahr

2023

Quelle

Electronic Journals Library

Beschreibungen/Notizen

• BACKGROUNDT-lymphoblastic lymphoma (T-LBL) is an aggressive malignancy of T-lymphoid precursors, rarely co-occurring with myeloid/lymphoid neoplasms with eosinophilia (M/LNs-Eo), with consequent rearrangement of tyrosine kinase (TK)-related genes. The FIP1L1-PDGFRA fusion gene is the most frequent molecular abnormality seen in eosinophilia-associated myeloproliferative disorders, but is also present in acute myeloid leukemia (AML), T-lymphoblastic leukemia/lymphoma (TLL), or both simultaneously. T-LBL mainly affects children and young adults, involving lymph node, bone marrow, and thymus. It represents about 85% of all immature lymphoblastic lymphomas, whereas immature B-cell lymphomas comprise approximately 15% of all cases of LBL. CASEIn this case report, we present an example of T cell lymphoblastic lymphoma with coexistent eosinophelia, treated successfully with a tyrosine-kinase inhibitor (TKI). CONCLUSIONFIP1L1-PDGFRA-positive T-LBL and myeloproliferative disorders have excellent response to low-dose treatment with (TKI) imatinib. Most patients achieve rapid and complete hematologic and molecular remission within weeks.